Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Shipping Orders ship quickly and discreetly from U.S
Although Retatrutide is not yet FDA approved, the encouraging results from the TRIUMPH-1 Phase 3 trials reveal its potential
ADA 2026: TRANSCEND-T2D-1: Retatrutide Demonstrates Robust Reductions in HbA1c and Body Weight as Monotherapy in Type 2 Diabetes The phase 3 TRANSCEND-T2D-1 trial evaluated the triple GIP, GLP-1, and glucagon receptor agonist in adults with type 2 diabetes inadequately controlled with diet and exercise alone
The FDA has approved these weight management agents for adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia
By activating three metabolic pathways simultaneously, it delivers faster and more comprehensive fat-burning effects than traditional single-agonist peptides
Photos two weeks apart often reveal what daily mirror checks miss entirely
US$ 22.04
US$ 22.08
US$ 22.82
US$ 23.87
US$ 22.34
US$ 20.07
US$ 28.97
US$ 26.20
US$ 28.17
